Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with the support of Cordis, is now available to watch.

The event featured distinguished speakers from Latin America and the United Kingdom and reached over 150 simultaneous attendees during the live broadcast.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Watch Again: Clinical Implications of Structural Heart Interventions — TAVI and MitraClip in Daily Practice

The recording of the webinar “Structural Interventions: TAVI and MitraClip in Daily Practice” is now available on the SOLACI YouTube channel. The activity was...

06/03 | SOLACI Technicians & Nurses Webinar – Clinical Impact of Structural Interventions: TAVI and MitraClip in Current Practice

The Latin American Society of Interventional Cardiology (SOLACI), through its Technicians and Nurses Department, invites you to participate in a new scientific webinar entitled...

Open Session | Current Endovascular Treatment of Tricuspid Regurgitation

SOLACI and the Argentine College of Interventional Cardioangiologists (CACI) invite you to participate in a new Open Session of the Advanced Postgraduate Course in...

SOLACI Presented an Outstanding Scientific Session on Complex Coronary Lesions at EuroPCR 2026

The Latin American Society of Interventional Cardiology (SOLACI) had a prominent participation at EuroPCR 2026 through an institutional scientific session held on May 21...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...